| Literature DB >> 34166331 |
Jill Diesel, Natalie Sterrett, Sharoda Dasgupta, Jennifer L Kriss, Vaughn Barry, Kayla Vanden Esschert, Ari Whiteman, Betsy L Cadwell, Daniel Weller, Judith R Qualters, LaTreace Harris, Achal Bhatt, Charnetta Williams, LeAnne M Fox, Dana Meaney Delman, Carla L Black, Kamil E Barbour.
Abstract
The U.S. COVID-19 vaccination program launched on December 14, 2020. The Advisory Committee on Immunization Practices recommended prioritizing COVID-19 vaccination for specific groups of the U.S. population who were at highest risk for COVID-19 hospitalization and death, including adults aged ≥75 years*; implementation varied by state, and eligibility was gradually expanded to persons aged ≥65 years beginning in January 2021. By April 19, 2021, eligibility was expanded to all adults aged ≥18 years nationwide.† To assess patterns of COVID-19 vaccination coverage among U.S. adults, CDC analyzed data submitted on vaccinations administered during December 14, 2020-May 22, 2021, by age, sex, and community-level characteristics. By May 22, 2021, 57.0% of persons aged ≥18 years had received ≥1 COVID-19 vaccine dose; coverage was highest among persons aged ≥65 years (80.0%) and lowest among persons aged 18-29 years (38.3%). During the week beginning February 7, 2021, vaccination initiation among adults aged ≥65 years peaked at 8.2%, whereas weekly initiation among other age groups peaked later and at lower levels. During April 19-May 22, 2021, the period following expanded eligibility to all adults, weekly initiation remained <4.0% and decreased for all age groups, including persons aged 18-29 years (3.6% to 1.9%) and 30-49 years (3.5% to 1.7%); based on the current rate of weekly initiation (as of May 22), younger persons will not reach the same levels of coverage as older persons by the end of August. Across all age groups, coverage (≥1 dose) was lower among men compared with women, except among adults aged ≥65 years, and lower among persons living in counties that were less urban, had higher social vulnerabilities, or had higher percentages of social determinants of poor health. Continued efforts to improve vaccination confidence and alleviate barriers to vaccination initiation, especially among adults aged 18-49 years, could improve vaccination coverage.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34166331 PMCID: PMC8224863 DOI: 10.15585/mmwr.mm7025e1
Source DB: PubMed Journal: MMWR Morb Mortal Wkly Rep ISSN: 0149-2195 Impact factor: 17.586
FIGURE 1Trends in COVID-19 vaccination cumulative coverage* and weekly initiation among adults, by epidemiologic week and age group — United States, December 14, 2020–May 22, 2021
* Coverage includes persons who received at least 1 dose of any Food and Drug Administration–authorized COVID-19 vaccine (≥1 dose; Pfizer-BioNTech, Moderna, or Janssen [Johnson & Johnson]).
† An epidemiologic week is based on the National Notifiable Diseases Surveillance System guidance and is assigned by the reporting local or state health department for the purposes of MMWR disease incidence reporting and publishing. The first day of any MMWR week is Sunday. https://wwwn.cdc.gov/nndss/document/MMWR_Week_overview.pdf
FIGURE 2COVID-19 vaccination second dose completion among adults who received ≥1 COVID-19 dose and had sufficient time to receive the second dose,* by age group — United States, December 14, 2020–May 22, 2021
* Analysis for second dose completion was restricted to persons who had received their first dose of a 2-dose vaccine (Pfizer-BioNTech or Moderna) during December 14, 2020–March 31, 2021. All persons included in the analysis for second dose completion were ≥42 days past their first dose.
† Excludes residents of Texas because Texas does not report information for age-specific dose number to CDC.
Coverage with ≥1 dose COVID-19 vaccine* among adults, by age group, sex, and county-level characteristics — United States, December 14, 2020—May 22, 2021
| Characteristic | Vaccine coverage | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Overall ≥18 yrs | 18–29 yrs | 30–49 yrs | 50–64 yrs | ≥65 yrs | ||||||
| (N = 255,200,373) | (n = 53,728,222) | (n = 84,488,200) | (n = 62,925,688) | (n = 54,058,263) | ||||||
| Estimate (%) | % Difference (95% CI) | Estimate (%) | % Difference (95% CI) | Estimate (%) | % Difference (95% CI) | Estimate (%) | % Difference (95% CI) | Estimate (%) | % Difference (95% CI) | |
|
|
|
| 37.6 | — | 48.5 | — | 62.9 | — | 79.1 | — |
|
| ||||||||||
| Female |
|
| 40.4 | Ref | 50.2 | Ref | 63.8 | Ref | 77.5 | Ref |
| Male |
|
| 34.0 | −6.4 (−7.8 to −5.1) | 45.5 | −4.7 (−5.7 to −3.6) | 60.3 | −3.5 (−4.4 to −2.7) | 79.9 | 2.4 (2.1 to 2.8) |
|
| ||||||||||
| Large central metro |
|
| 41.0 | Ref | 50.9 | Ref | 63.2 | Ref | 74.8 | Ref |
| Large fringe metro |
|
| 40.3 | −0.7 (−9.0 to 7.5) | 49.8 | −1.2 (−10.6 to 8.2) | 64.1 | 0.9 (−9.3 to 11.1) | 79.7 | 4.9 (−3.4 to 13.2) |
| Medium metro |
|
| 33.3 | −7.7 (−15.9 to 0.5) | 44.9 | −6.1 (−16.0 to 3.9) | 60.4 | −2.8 (−13.5 to 8.0) | 79.0 | 4.2 (−4.4 to 12.9) |
| Small metro |
|
| 28.5 | −12.5 (−21.9 to −3.1) | 39.6 | −11.4 (−22.6 to −0.2) | 54.3 | −8.9 (−20.9 to 3.0) | 73.8 | −1.0 (−11.0 to 9.0) |
| Micropolitan |
|
| 23.6 | −17.4 (−27.4 to −7.3) | 34.5 | −16.4 (−28.3 to −4.5) | 50.8 | −12.4 (−24.9 to 0) | 71.2 | −3.6 (−13.3 to 6.1) |
| Noncore |
|
| 20.1 | −20.9 (−31.2 to −10.6) | 29.7 | −21.3 (−33.2 to −9.3) | 45.8 | −17.4 (−29.4 to −5.4) | 65.4 | −9.4 (−18.2 to −0.7) |
|
| ||||||||||
| Low vulnerability | ||||||||||
| <25th percentile |
|
| 42.1 | Ref | 51.6 | Ref | 64.5 | Ref | 80.9 | Ref |
| 25th to <50th percentile |
|
| 40.0 | −2.1 (−8.2 to 4.0) | 51.0 | −0.6 (−7.3 to 6.2) | 63.4 | −1.2 (−6.4 to 4.1) | 80.4 | −0.4 (−3.4 to 2.5) |
| 50th to <75th percentile |
|
| 33.9 | −8.1 (−13.7 to −2.6) | 44.2 | −7.4 (−13.3 to −1.5) | 58.3 | −6.2 (−12.9 to 0.4) | 74.5 | −6.4 (−13.4 to 0.6) |
| High vulnerability | ||||||||||
| ≥75th percentile |
|
| 28.5 | −13.5 (−22.6 to −4.5) | 39.2 | −12.4 (−22.2 to −2.6) | 53.9 | −10.6 (−22.3 to 1.0) | 67.4 | −13.5 (−25.9 to −1.0) |
|
| ||||||||||
| Below median (<50th percentile) |
|
| 34.7 | Ref | 44.1 | Ref | 57.4 | Ref | 75.2 | Ref |
| At or above median (≥50th percentile) |
|
| 35.9 | 1.2 (−3.3 to 5.6) | 47.0 | 2.9 (−1.7 to 7.5) | 61.0 | 3.6 (−0.7 to 7.9) | 76.0 | 0.8 (−2.7 to 4.4) |
|
| ||||||||||
| Below median (<50th percentile) |
|
| 42.7 | Ref | 54.7 | Ref | 67.8 | Ref | 83.0 | Ref |
| At or above median (≥50th percentile) |
|
| 27.2 | −15.5 (−26.4 to −4.6) | 36.3 | −18.4 (−32.9 to −4.0) | 50.2 | −17.6 (−35.2 to 0.0) | 66.9 | −16.1 (−36.6 to 4.3) |
|
| ||||||||||
| Below median (<50th percentile) |
|
| 40.0 | Ref | 50.0 | Ref | 63.5 | Ref | 79.7 | Ref |
| At or above median (≥50th percentile) |
|
| 30.4 | −9.6 (−13.4 to −5.9) | 41.0 | −9.0 (−13.4 to −4.5) | 54.8 | −8.7 (−13.6 to −3.8) | 70.3 | −9.3 (−14.8 to −3.8) |
|
| ||||||||||
| Below median (<50th percentile) |
|
| 37.7 | Ref | 48.4 | Ref | 62.1 | Ref | 77.6 | Ref |
| At or above median (≥50th percentile) |
|
| 24.0 | −13.7 (−19.3 to −8.1) | 34.2 | −14.2 (−20.8 to −7.6) | 49.5 | −12.6 (−18.4 to −6.8) | 67.7 | −9.9 (−13.9 to −5.9) |
|
| ||||||||||
| Below median (<50th percentile) |
|
| 39.5 | Ref | 50.0 | Ref | 63.5 | Ref | 79.0 | Ref |
| At or above median (≥50th percentile) |
|
| 23.6 | −15.9 (−20.5 to −11.3) | 33.7 | −16.3 (−21.9 to −10.7) | 48.7 | −14.7 (−21.4 to −8.0) | 65.9 | −13.1 (−21.6 to −4.6) |
|
| ||||||||||
| Below median (<50th percentile) |
|
| 29.1 | Ref | 39.9 | Ref | 55.4 | Ref | 75.9 | Ref |
| At or above median (≥50th percentile) |
|
| 36.8 | 7.7 (−1.1 to 16.6) | 47.4 | 7.4 (−3.7 to 18.6) | 61.0 | 5.6 (−6.5 to 17.7) | 75.7 | −0.1 (−12.9 to 12.6) |
Abbreviations: CI = confidence interval; NCHS = National Center for Health Statistics; Ref = referent group; SVI = Social Vulnerability Index.
* All models exclude persons with missing state of residence (modeled overall coverage is slightly lower than shown in descriptive results).
† Persons with sex reported as “unknown” (N = 1,627,296) were excluded from the table (≥18 years, n = 1,627,296; 18–29 years, n = 242,601; 30–49 years, n = 578,940; 50–64 years, n = 504,173; ≥65 years, n = 301,582).
§ The following jurisdictions were excluded from all county-level analyses (NCHS urban-rural, SVI, and Social Determinants of Health) due to lack of county-level vaccination data: all counties in Hawaii and eight counties in California for which total population was <20,000. Among all first doses analyzed during December 14, 2020–May 22, 2021, 5.9% were missing county data and were therefore excluded from models.
¶ Categories of county-level urbanicity based on the 2013 NCHS urban-rural classification scheme. https://www.cdc.gov/nchs/data_access/urban_rural.htm#2013_Urban-Rural_Classification_Scheme_for_Counties
** Fifteen elements categorized into four themes (socioeconomic status, household composition and disability, racial/ethnic minority status and language, and housing type and transportation) are included in SVI (https://www.atsdr.cdc.gov/placeandhealth/svi/documentation/pdf/SVI2018Documentation-H.pdf). Overall SVI includes all 15 indicators as a composite measure (https://www.atsdr.cdc.gov/placeandhealth/svi/fact_sheet/fact_sheet.html). One county in New Mexico was excluded because SVI ranking could not be calculated (https://www.atsdr.cdc.gov/placeandhealth/svi/index.html).
†† Measures of Social Determinants of Health from the American Community Survey: percentage of the total population 1) unemployed, 2) uninsured, 3) that earned an income below the federal poverty level, 4) without a computer (e.g., desktop or laptop computer [excludes mobile phones]), 5) with a computer but without Internet access, and 6) identifying as a racial/ethnic group other than non-Hispanic White (https://health.gov/healthypeople/objectives-and-data/social-determinants-health).